Gain- and loss-of-function mutations in the breast cancer gene GATA3 result in differential drug sensitivity
Patterns of somatic mutations in cancer genes provide information about their functional role in tumourigenesis and thus indicate their potential for therapeutic exploitation. Yet, the classical distinction between oncogene and tumour suppressor may not always apply. For instance, TP53 has been simu...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Public Library of Science
2016
|
| _version_ | 1826257257563684864 |
|---|---|
| author | Mair, B Konopka, T Kerzendorfer, C Sleiman, K Salic, S Serra, V Muellner, M Theodorou, V Nijman, S |
| author_facet | Mair, B Konopka, T Kerzendorfer, C Sleiman, K Salic, S Serra, V Muellner, M Theodorou, V Nijman, S |
| author_sort | Mair, B |
| collection | OXFORD |
| description | Patterns of somatic mutations in cancer genes provide information about their functional role in tumourigenesis and thus indicate their potential for therapeutic exploitation. Yet, the classical distinction between oncogene and tumour suppressor may not always apply. For instance, TP53 has been simultaneously associated with tumour suppressing and promoting activities. Here, we uncover a similar phenomenon for GATA3, a frequently mutated, yet poorly understood breast cancer gene. We identify two functional classes of frameshift mutations that are associated with distinct expression profiles in tumours, differential disease-free patient survival and gain- and loss-of-function activities in a cell line model. Furthermore, we find an estrogen receptor-independent synthetic lethal interaction between a GATA3 frameshift mutant with an extended C-terminus and the histone methyltransferases G9A and GLP, indicating perturbed epigenetic regulation. Our findings reveal important insights into mutant GATA3 function and breast cancer, provide the first potential therapeutic strategy and suggest that dual tumour suppressive and oncogenic activities are more widespread than previously appreciated. |
| first_indexed | 2024-03-06T18:15:18Z |
| format | Journal article |
| id | oxford-uuid:04685567-aec1-47f9-9586-e9c21ba1c08e |
| institution | University of Oxford |
| last_indexed | 2024-03-06T18:15:18Z |
| publishDate | 2016 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:04685567-aec1-47f9-9586-e9c21ba1c08e2022-03-26T08:51:38ZGain- and loss-of-function mutations in the breast cancer gene GATA3 result in differential drug sensitivityJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:04685567-aec1-47f9-9586-e9c21ba1c08eSymplectic Elements at OxfordPublic Library of Science2016Mair, BKonopka, TKerzendorfer, CSleiman, KSalic, SSerra, VMuellner, MTheodorou, VNijman, SPatterns of somatic mutations in cancer genes provide information about their functional role in tumourigenesis and thus indicate their potential for therapeutic exploitation. Yet, the classical distinction between oncogene and tumour suppressor may not always apply. For instance, TP53 has been simultaneously associated with tumour suppressing and promoting activities. Here, we uncover a similar phenomenon for GATA3, a frequently mutated, yet poorly understood breast cancer gene. We identify two functional classes of frameshift mutations that are associated with distinct expression profiles in tumours, differential disease-free patient survival and gain- and loss-of-function activities in a cell line model. Furthermore, we find an estrogen receptor-independent synthetic lethal interaction between a GATA3 frameshift mutant with an extended C-terminus and the histone methyltransferases G9A and GLP, indicating perturbed epigenetic regulation. Our findings reveal important insights into mutant GATA3 function and breast cancer, provide the first potential therapeutic strategy and suggest that dual tumour suppressive and oncogenic activities are more widespread than previously appreciated. |
| spellingShingle | Mair, B Konopka, T Kerzendorfer, C Sleiman, K Salic, S Serra, V Muellner, M Theodorou, V Nijman, S Gain- and loss-of-function mutations in the breast cancer gene GATA3 result in differential drug sensitivity |
| title | Gain- and loss-of-function mutations in the breast cancer gene GATA3 result in differential drug sensitivity |
| title_full | Gain- and loss-of-function mutations in the breast cancer gene GATA3 result in differential drug sensitivity |
| title_fullStr | Gain- and loss-of-function mutations in the breast cancer gene GATA3 result in differential drug sensitivity |
| title_full_unstemmed | Gain- and loss-of-function mutations in the breast cancer gene GATA3 result in differential drug sensitivity |
| title_short | Gain- and loss-of-function mutations in the breast cancer gene GATA3 result in differential drug sensitivity |
| title_sort | gain and loss of function mutations in the breast cancer gene gata3 result in differential drug sensitivity |
| work_keys_str_mv | AT mairb gainandlossoffunctionmutationsinthebreastcancergenegata3resultindifferentialdrugsensitivity AT konopkat gainandlossoffunctionmutationsinthebreastcancergenegata3resultindifferentialdrugsensitivity AT kerzendorferc gainandlossoffunctionmutationsinthebreastcancergenegata3resultindifferentialdrugsensitivity AT sleimank gainandlossoffunctionmutationsinthebreastcancergenegata3resultindifferentialdrugsensitivity AT salics gainandlossoffunctionmutationsinthebreastcancergenegata3resultindifferentialdrugsensitivity AT serrav gainandlossoffunctionmutationsinthebreastcancergenegata3resultindifferentialdrugsensitivity AT muellnerm gainandlossoffunctionmutationsinthebreastcancergenegata3resultindifferentialdrugsensitivity AT theodorouv gainandlossoffunctionmutationsinthebreastcancergenegata3resultindifferentialdrugsensitivity AT nijmans gainandlossoffunctionmutationsinthebreastcancergenegata3resultindifferentialdrugsensitivity |